• Type of Event: The document is a regulatory filing containing the full transcript of the Q1 FY27 Earnings Conference Call for analysts and investors.
  • Date and Time: The conference call was conducted through digital means on Thursday, 30th July, 2026, at 03:30 P.M. (IST).
  • Purpose: The purpose of the call was to discuss the company's financial results for the first quarter of the financial year 2026-27 (Q1 FY27).
  • Earnings Announcement: The call was held after the earnings announcement for the quarter.
  • Management Participants: The following management representatives participated in the call:
  • Mr. R.V. Bubna – Chairman and Managing Director
  • Mr. Shailesh Mehendale – Chief Financial Officer (CFO)
  • Mr. Jetkin Gudhka – Company Secretary
  • Availability of Materials: The transcript was filed with the exchanges and is also available on the company's website at www.shardacropchem.com. An investor presentation (deck) was referenced as having been shared with participants prior to the call.
  • UPSI Statement: The document is a factual transcript of the call and does not contain any separate statement indicating that no Unpublished Price Sensitive Information (UPSI) would be shared.

Financial Highlights & Guidance (As Disclosed in the Call):

  • Financial Period: Q1 FY27 (Quarter ending June 30, 2026).
  • Revenue: Stood at ₹1,074 crores, an increase of 9% Year-on-Year (YoY) from ₹985 crores in Q1 FY26.
  • Business Split: Agrochemical business grew 8% YoY to ₹915 crores; Non-Agrochemical business grew 15% YoY to ₹159 crores.
  • Gross Margin: Expanded by 120 basis points (bps) YoY to 36.7% from 35.5%.
  • EBITDA: Grew 25% YoY to ₹178 crores. EBITDA margin expanded by 220 bps YoY to 16.6% from 14.4%.
  • Forex Gain: Was ₹7.5 crores in Q1 FY27, significantly lower than the ₹73.1 crores gain in Q1 FY26 due to currency movement volatility.
  • Profitability: PAT stood at ₹88 crores. On a like-to-like basis, excluding the forex gain, PBT grew 16% YoY to ₹111 crores.
  • Balance Sheet: The company remains debt-free. Cash, bank, and liquid investments stood at ₹767 crores as of June 30, 2026, up from ₹702 crores on March 31, 2026. Total equity was ₹3,245 crores.
  • Working Capital: Working capital days improved to 88 days as of June 30, 2026, from 98 days on March 31, 2026.
  • Product Registrations: Total registrations reached 3,016 as of June 30, 2026, up from 3,011 on March 31, 2026. An additional 1,027 applications are at the approval stage.
  • Regional Performance: Revenue in Europe softened due to distributor destocking caused by heatwave conditions, though margins in the region improved. NAFTA and LATAM regions delivered strong growth.
  • Guidance: Management reiterated its FY27 guidance of 10%-15% revenue growth and gross margins around 35%. They expect EBITDA margins to be in the range of 18%-20% for the full year. Volume growth for the year is expected to be 5%-10%.

Key Q&A Takeaways (As Disclosed):

  • Volume/R realization Split for 9% Growth: Volume growth was -1.6%, Forex impact was +12.7%, and product mix impact was -2.1%.
  • Europe Volume Dip: Attributed to temporary distributor destocking due to heatwaves. Management stated the situation has since normalized.
  • Forex Gain Volatility: Explained as unrealized mark-to-market gains/losses on foreign currency trade receivables and payables, repriced at each quarter-end. The large gain in Q1 FY26 was due to a ~10% appreciation of the Euro vs. USD in that quarter.
  • Business Model: Confirmed the company is 100% contract manufactured, primarily in China.
  • Tax Rate: The effective tax rate for the quarter was higher at ~26%, but the annualized rate is expected to normalize to 18%-20%.
  • Region-wise Gross Margins (Q1 FY27 vs Q1 FY26): Europe: 44.2% (vs 42.9%); NAFTA: 32.8% (vs 25.9%); LATAM: 16.9% (vs 28.0%); Rest of World: 30.8% (vs 26.8%).
  • Region-wise Registration Count (June '26 vs Mar '26): Europe: 1,682 (vs 1,679); NAFTA: 325 (vs 323); LATAM: 760 (vs 760); Rest of World: 249 (vs 249).

Additional Notes Section

  • The document is a regulatory filing submitted to the BSE and NSE. The enclosed attachment was the earnings call transcript itself.
  • The announcement itself did not disclose primary financial data; it was an intimation of the transcript's availability. The financial figures summarized above are extracted from the content of the enclosed transcript.